Bioequivalence and Bioavailability Forum 04:07 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

ElMaestro
Hero

Denmark,
2018-04-15 14:50

Posting: # 18684
Views: 641
 

 Shenanigans [BE/BA News]

Hi all,

story from New York Times.

I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,939 posts in 4,040 threads, 1,288 registered users;
online 6 (1 registered, 5 guests [including 4 identified bots]).

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed